Business Context and Reporting Period
This Form 8-K is filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) for the reporting period of November 22, 2017. The filing addresses a corporate governance issue regarding the composition of the Board of Directors and its impact on continued listing standards with the NYSE American.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance and corporate governance rather than financial performance.
Material Changes
- Board Composition: The departure of Don M. Bailey from the Board of Directors resulted in the Board no longer having a majority of independent directors.
- Listing Status: The company is currently not in compliance with Section 802(a) of the Exchange Company Guide regarding independent director requirements.
- Regulatory Notice: On November 27, 2017, the company received an official notice of noncompliance from the NYSE American.
Outlook, Risks, and Management Commentary
Management plans to recruit a new independent director to fill the vacancy and regain compliance with the Exchange's board composition requirements. The company has been granted a grace period to comply: until the next annual meeting of shareholders or one year from the date of Mr. Bailey's departure. If the next annual meeting occurs within 180 days of the departure, the compliance deadline is 180 days from the departure date. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10.
Investor Verification Checklist
- Verify the current status of the Board of Directors and whether a new independent director has been appointed.
- Confirm the date of the next annual meeting of shareholders to determine the exact compliance deadline.
- Review the company's Form 10 for detailed risk factors associated with potential delisting or governance instability.
- Check for any subsequent filings regarding the company's stock listing status on the NYSE American.